By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Synvista Therapeutics 

221 West Grand Avenue

Montvale  New Jersey  07645  U.S.A.
Phone: 201-934-5000 Fax: 201-934-8880


Company News
Synvista Therapeutics Announces Restructuring of Dividend Obligation to Preferred Stockholders and Decision to Delist from NYSE Alternext and Terminate SEC Registration of Common Stock 2/25/2009 8:40:38 AM
Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update 1/29/2009 6:58:05 AM
Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium 1/12/2009 9:36:01 AM
Synvista Therapeutics Notified by NYSE Alternext of Continued Listing Standards Non-Compliance 12/29/2008 10:56:59 AM
Synvista Therapeutics Announces Published Data Demonstrating Elevation of Carboxymethyl-Lysine (CML) Is Associated with Decline in Renal Function and Arterial Stiffness in Older Adults 12/16/2008 8:44:50 AM
Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis 12/15/2008 8:05:26 AM
Synvista Therapeutics Announces 510(k) Submission for Its HAPTOCHEK(TM) Test Kit 11/19/2008 8:00:31 AM
Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During American Heart Association Meeting 11/11/2008 9:59:46 AM
Synvista Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference 11/10/2008 1:22:14 PM
Synvista Therapeutics Announces Availability of Haptoglobin Genotyping Technology at The Annual Scientific Sessions of the American Heart Association 11/10/2008 1:14:17 PM